Skip to main content
SpringerLink
Log in

Molekularpathologische KRAS-Mutationsanalyse

Voraussetzung für die zielgerichtete Antikörpertherapie des metastasierten kolorektalen Karzinoms

Molecular pathologic KRAS mutation analysis

A prerequisite of effective antibody treatment for metastasized colorectal cancer

  • Klinische Studien
  • Published:
Der Chirurg Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1

Literatur

  1. Amado RG, Wolf M, Freeman D et al. (2007) Wild-type KRAS is required for Panitumumab efficacy in patients with metastatic colorectal cancer: results from a randomized, controlled trial. EJC [Suppl] 5: 7LB

  2. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al. (2007) Oncogenic activation of the RAS/RAF signalling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67: 2643–2648

    Article  PubMed  CAS  Google Scholar 

  3. Berlin J, Van Cutsem E, Peeters M et al. (2006) Safety and efficacy of Panitumumab monotherapy in the treatment of metastatic colorectal cancer (mCRC) summary of results across clinical studies. Ann Oncol 17 [Suppl] 9:ix114, Abstract 326O

  4. De Roock W, Piessevaux H, De Schutter J et al. (2008) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol (in press)

  5. Freeman D, Juan T, Meropol NJ et al. (2007) Association of somatic KRAS gene mutations and clinical outcome in patients with metastatic colorectal cancer receiving Panitumumab monotherapy. EJC [Suppl] 5: 3014

  6. Siena S, Peeters M, Van Cutsem E et al. (2007) Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Br J Cancer 97: 1469–1474

    Article  PubMed  CAS  Google Scholar 

  7. Tabernero J, Van Cutsem E, Díaz-Rubio E et al. (2007) Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 25: 5225–5232

    Article  PubMed  CAS  Google Scholar 

  8. Van Cutsem E, Peeters M, Siena S et al. (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658–1664

    Article  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Institut für Pathologie, Charité - Universitätsmedizin Berlin,Campus Mitte, Charitéplatz 1, 10117, Berlin, Deutschland

    M. Dietel

  2. Institut für Pathologie, Ruhr-Universität , Bochum, Deutschland

    A. Tannapfel

  3. Institut für Pathologie, Universitätsklinikum, Dresden, Deutschland

    G. Baretton

  4. Institut für Pathologie, Medizinische Hochschule, Hannover, Deutschland

    H. Kreipe

  5. Institut für Pathologie, Universitätsklinikum Heidelberg, Heidelberg, Deutschland

    M. Kloor

  6. Institut für Pathologie der Heinrich-Heine-Universität, Düsseldorf, Deutschland

    H. Gabbert

  7. Pathologisches Institut der LMU, München, Deutschland

    T. Kirchner

Authors
  1. M. Dietel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Tannapfel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Baretton
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Kreipe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Kloor
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H. Gabbert
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T. Kirchner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Dietel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dietel, M., Tannapfel, A., Baretton, G. et al. Molekularpathologische KRAS-Mutationsanalyse. Chirurg 79, 576–579 (2008). https://doi.org/10.1007/s00104-008-1514-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00104-008-1514-x

Search

Navigation